Calithera Biosciences, Inc. (NASDAQ:CALA) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

Item5.02

On May10, 2017, the Compensation Committee of the Board of
Directors, approved an amendment to the 2017 performance bonus
program by increasing the total 2017 target performance bonus as
a percentage of base salary for Keith Orford, M.D., Ph.D. from
35% to 40%. The 2017 annual performance bonuses for each other
named executive officer are otherwise as set forth in our current
report on Form 8-K filed with the Securities and Exchange
Commission on March13, 2017.

About Calithera Biosciences, Inc. (NASDAQ:CALA)

Calithera Biosciences, Inc. is a clinical-stage pharmaceutical company. The Company focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells. Its lead product candidate, CB-839, is a critical enzyme in tumor cells. Its other product candidate, CB-1158, which is an enzyme that depletes the amino acid arginine, a key metabolic nutrient for T-cells. Its lead preclinical program in tumor immunology is directed at developing inhibitors of the enzyme arginase and may provide a therapeutic agent for the target. CB-839 is a selective, reversible and orally bioavailable inhibitor of human glutaminase. Hexokinase is an enzyme in the pathway that allows cancer cells to convert glucose to energy to fuel cancer cell growth.

Calithera Biosciences, Inc. (NASDAQ:CALA) Recent Trading Information

Calithera Biosciences, Inc. (NASDAQ:CALA) closed its last trading session up +0.65 at 14.25 with 689,637 shares trading hands.